Page last updated: 2024-10-19

nitrites and Hemolysis

nitrites has been researched along with Hemolysis in 39 studies

Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)

Hemolysis: The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.

Research Excerpts

ExcerptRelevanceReference
" In parallel, hemolysis was assessed by measuring cell-free hemoglobin (Hb) and free heme (hemin)."3.81Predicting storage-dependent damage to red blood cells using nitrite oxidation kinetics, peroxiredoxin-2 oxidation, and hemoglobin and free heme measurements. ( Harper, V; Marques, MB; Oh, JY; Patel, RP; Stapley, R, 2015)
"In this study, we aimed to investigate the relationship between chronic hemolysis and increased body iron burden with development of premature atherosclerosis by carotid intima-media thickness (IMT), ferritin, serum lipid profile, homocysteine, nitrate/nitrite, and chitotriosidase enzyme activity in children with β-thalassemia major."3.78Premature atherosclerosis in children with β-thalassemia major. ( Altun, D; Aydin, A; Gursel, O; Ileri, T; Kocaoglu, M; Kurekci, AE; Kurt, I; Okutan, V; Ozcan, O; Tapan, S; Tascilar, E, 2012)
"Blood withdrawal and reactive hyperemia index measurements were performed before and 10 min, 1 h, 2 h, and 4 h after transfusion."2.77Transfusion of stored autologous blood does not alter reactive hyperemia index in healthy volunteers. ( Berra, L; Bloch, KD; Coppadoro, A; Dzik, WH; Feelisch, M; Fernandez, BO; Lei, C; Lin, T; Sammy, FY; Spagnolli, E; Steinbicker, AU; Stowell, CP; Warren, HS; Yu, B; Zapol, WM, 2012)
" The data also suggest that concomitant treatment with NAR can restore NO bioavailability through either its metal-chelating properties or its antioxidant activity."1.40Erythrocyte nitric oxide synthase as a surrogate marker for mercury-induced vascular damage: the modulatory effects of naringin. ( Abo-Salem, OM; Attiaa, SM; Harisa, GI; Mariee, AD, 2014)
"Plasma hemoglobin (Hb) released during intravascular hemolysis has been associated with numerous deleterious effects that may stem from increased nitric oxide (NO) scavenging, but has also been associated with reactive oxygen species generation and platelet activation."1.38Angeli's salt counteracts the vasoactive effects of elevated plasma hemoglobin. ( Bellavia, L; Bruce King, S; Ferreyra, GA; Gladwin, MT; Helms, CC; Kern, SJ; Kim-Shapiro, DB; McPhail, LC; Natanson, C; Perlegas, A; Piknova, B; Raat, NJ; Schechter, AN; Solomon, SB; Sun, J; Sweeney, D, 2012)

Research

Studies (39)

TimeframeStudies, this research(%)All Research%
pre-199016 (41.03)18.7374
1990's0 (0.00)18.2507
2000's8 (20.51)29.6817
2010's14 (35.90)24.3611
2020's1 (2.56)2.80

Authors

AuthorsStudies
Bezerra, ÉA1
Alves, MMM1
Amorim, LV1
Carvalho, RCV1
Cruz, LPL1
Costa-Júnior, JS1
Oliveira, MDDA1
Lima Neto, JS1
Carvalho, FAA1
Citó, AMDGL1
Arcanjo, DDR1
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y3
Wang, J6
Huang, L2
Hu, K1
Liu, H4
Wang, H3
Guo, Z1
Song, Y1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S1
Cheng, T1
Zhou, X1
Wang, B4
Zhang, Q4
Wu, X2
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W2
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X4
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J4
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J2
Jiang, H1
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X4
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Liu, Z3
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Zhang, X6
Xu, N1
Wang, R1
Liu, S1
He, H1
Dong, X2
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L2
Yang, X1
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH2
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C2
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Zhang, Y6
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y7
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L4
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X2
Xu, H2
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Li, J7
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Liu, Y7
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H1
Yu, B3
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J3
Chu, S1
Pan, Q1
Li, D2
Zheng, S2
Ma, L1
Wang, L3
Hu, T1
Wang, F1
Han, Z1
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y3
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y4
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z2
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J3
Guo, W1
Liu, M2
Liu, T3
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Zhang, S2
Feng, J2
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z2
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J1
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C2
Liu, W1
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y1
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q1
Yuan, X1
Nie, W1
Yang, J2
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L3
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Li, C2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X3
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J1
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z2
Liang, H1
Xu, X1
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J2
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H1
Zhang, W1
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J1
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J2
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L1
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Machado, KDC2
Oliveira, GLDS1
Islam, MT1
de Almeida, AAC1
Junior, ALG1
de Sousa, DP1
Melo-Cavalcante, AAC1
de Freitas, RM1
Fedorov, SM1
Baziliuk, OV1
Kotsiuruba, AV1
Korkach, IuP1
Sahach, VF1
Harisa, GI2
Mariee, AD1
Abo-Salem, OM1
Attiaa, SM1
Ramírez-Zamora, S1
Méndez-Rodríguez, ML1
Olguín-Martínez, M1
Sánchez-Sevilla, L1
Quintana-Quintana, M1
García-García, N1
Hernández-Muñoz, R1
Oh, JY1
Stapley, R1
Harper, V1
Marques, MB1
Patel, RP3
Nagababu, E1
Scott, AV1
Johnson, DJ1
Goyal, A1
Lipsitz, JA1
Barodka, VM1
Berkowitz, DE1
Frank, SM1
de Oliveira, GAL1
da Silva Oliveira, GL1
Nicolau, LAD1
Mafud, AC1
Batista, LF1
Mascarenhas, YP1
de Sousa, LKM1
David, JM1
Pinto, LS1
Alves, CQ1
Medeiros, JVR1
Nan, YH1
Shin, SY1
Makkar, HP1
Siddhuraju, P1
Becker, K1
Blood, AB1
Schroeder, HJ1
Terry, MH1
Merrill-Henry, J1
Bragg, SL1
Vrancken, K1
Herring, JL1
Sowers, LC1
Wilson, SM1
Power, GG1
Berra, L1
Coppadoro, A1
Lei, C1
Spagnolli, E1
Steinbicker, AU1
Bloch, KD1
Lin, T1
Sammy, FY1
Warren, HS1
Fernandez, BO1
Feelisch, M1
Dzik, WH1
Stowell, CP1
Zapol, WM1
Alanazi, FK1
El-Bassat, RA1
Malik, A1
Abdallah, GM1
Solomon, SB1
Bellavia, L1
Sweeney, D1
Piknova, B1
Perlegas, A1
Helms, CC1
Ferreyra, GA1
Bruce King, S1
Raat, NJ1
Kern, SJ1
McPhail, LC1
Schechter, AN1
Natanson, C1
Gladwin, MT2
Kim-Shapiro, DB1
Gursel, O1
Kurekci, AE1
Tascilar, E1
Ileri, T1
Altun, D1
Tapan, S1
Kurt, I1
Kocaoglu, M1
Aydin, A1
Okutan, V1
Ozcan, O1
Xiang, W1
Weisbach, V1
Sticht, H1
Seebahn, A1
Bussmann, J1
Zimmermann, R1
Becker, CM1
Zavodnik, IB1
Lapshina, EA1
Zavodnik, LB1
Soszyński, M1
Bartosz, G1
Bryszewska, M1
Pascutti, MF1
Bottasso, OA1
Hourquescos, MC1
Wietzerbin, J1
Revelli, S1
LEYKO, W1
DIMOCHOWSKI, A1
BOLANOWSKA, W1
LORENC, J1
Crawford, JH2
Chacko, BK1
Kevil, CG1
Narendra, M1
Bhatracharyulu, NC1
Padmavathi, P1
Varadacharyulu, NC1
Dodge, JT1
Cohen, G1
Kayden, HJ1
Phillips, GB1
Singelmann, E1
Wetzel, E1
Adler, G1
Steffen, C1
Smith, RC1
Nunn, V1
Ring, A1
Braun, JS1
Nizet, V1
Stremmel, W1
Shenep, JL1
Berger, U1
Pervanidis, A1
Baird, JK1
Davidson, DE1
Decker-Jackson, JE1
Hauschild, AH1
Hilsheimer, R1
Griffith, DW1
Smith, RP2
Kruszyna, H1
Pedersen, KB1
Osborne, CK1
Carolla, R1
Jefferson, D1
Mengel, CE1
Pearlman, FC1
Lee, RT1
Tudhope, GR1
Leece, SP1
Jung, F1
Kahl, R1
D'Elia, R1
McClatchy, JK1
Rosenblum, ED1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Red Cell Storage Duration Study[NCT00991341]Phase 31,481 participants (Actual)Interventional2010-01-31Completed
A Safety and Efficacy Evaluation of Sodium Nitrite Injection for the Treatment of Vaso-Occlusive Crisis Associated With Sickle Cell Disease[NCT01033227]Phase 1/Phase 25 participants (Actual)Interventional2009-12-31Terminated (stopped due to Low enrollment)
Phase I/II Study of Simvastatin (Zocor) Therapy in Sickle Cell Disease[NCT00508027]Phase 1/Phase 242 participants (Actual)Interventional2007-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

All-cause Mortality

Subjects were randomized for RECESS no earlier than one calendar day before the planned date of surgery, and were followed for all-cause mortality until post-operative Day 28, death, or study withdrawal, whichever occurred first. In some cases the surgery was postponed after randomization had already occurred. If surgery did not occur within 30 days after randomization, the subject ended the study and was not considered evaluable. If surgery did occur within 30 days after randomization, and the subject received at least one RBC transfusion between randomization and 96 hours after the end of surgery, the subject was considered evaluable. Therefore, in a few evaluable subjects, post-operative Day 28 could be nearly two months after the date of randomization. The times in the time-to-event analysis started at randomization. (NCT00991341)
Timeframe: 28 days post-surgery

Interventionparticipants with event (Number)
Shorter-storage Red Blood Cell Units23
Longer-storage Red Blood Cell Units29

Any Mechanical Ventilation More Than 48 Hours Post-operation

(NCT00991341)
Timeframe: 48 hours post-operation through day 28, hospital discharge, or death, whichever occurs first

Interventionparticipants with event (Number)
Shorter-storage Red Blood Cell Units68
Longer-storage Red Blood Cell Units80

Change in Bilirubin From Pre-operative Value to Worst Post-operative Value

(NCT00991341)
Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Interventionmg/dL (Mean)
Shorter-storage Red Blood Cell Units0.85
Longer-storage Red Blood Cell Units1.49

Change in Lactate From Pre-operative Value to Worst Post-operative Value

The arterial lactate levels were adjusted to make them comparable to venous lactate levels. (NCT00991341)
Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Interventionmmol/L (Mean)
Shorter-storage Red Blood Cell Units2.30
Longer-storage Red Blood Cell Units2.92

Change in Multiple Organ Dysfunction Score From Pre-operative Baseline.

The follow-up MODS used to calculate 28-day ΔMODS from pre-op baseline was based on the worst value of each component of MODS observed through post-op day 28, hospital discharge, or death, whichever occurred first, even if a subject's worst values for different components occurred on different dates. Subjects who died during this time period were assigned the worst possible follow-up MODS score, 24 points, and each component of MODS was set at 4, which is the worst score. If a subject did not die during this time period but had at least one day where the Glasgow Coma Score couldn't be scored[subject sedated; neurologic function not normal by pre-op history (prior stroke, tumor or trauma sequelae, cognitively challenged, behavioral disorder, etc.) or intra-op history, but currently unable to assess because of sedation], then a post-op MODS score was set to missing and a 28-day ΔMODS was not computed. The total MODS score ranges from 0 (best possible) to 24 points (worst possible). (NCT00991341)
Timeframe: Through 28 days post-surgery, hospital discharge, or death, whichever occurs first

InterventionMOD score points (Mean)
Shorter-storage Red Blood Cell Units8.74
Longer-storage Red Blood Cell Units9.07

Change in Serum Creatinine From Pre-operative Value to Worst Post-operative Value

(NCT00991341)
Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Interventionmg/dL (Mean)
Shorter-storage Red Blood Cell Units0.35
Longer-storage Red Blood Cell Units0.35

Change in Troponin-I From Pre-operative Value to Worst Post-operative Value

(NCT00991341)
Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Interventionng/mL (Mean)
Shorter-storage Red Blood Cell Units15.82
Longer-storage Red Blood Cell Units14.06

Composite of Major Cardiac Events (Death, Myocardial Infarction, Low Cardiac Output, Ventricular Tachycardia, Ventricular Fibrillation)

(NCT00991341)
Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Interventionparticipants with event (Number)
Shorter-storage Red Blood Cell Units206
Longer-storage Red Blood Cell Units230

Composite of Major In-hospital Post-operative Complications (Death, Stroke, Myocardial Infarction, Renal Failure, Culture-proven Sepsis/Septic Shock)

(NCT00991341)
Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Interventionparticipants with event (Number)
Shorter-storage Red Blood Cell Units91
Longer-storage Red Blood Cell Units87

Composite of Major Pulmonary Events (Any Mechanical Ventilation From 48 Hours Post-operation to Day 7, Hospital Discharge or Death, Whichever Comes First, or Pulmonary Embolism)

(NCT00991341)
Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Interventionparticipants with event (Number)
Shorter-storage Red Blood Cell Units62
Longer-storage Red Blood Cell Units75

Days Alive and Ventilator Free Through Post-op Day 28

(NCT00991341)
Timeframe: Through post-op day 28

Interventiondays (Mean)
Shorter-storage Red Blood Cell Units25.38
Longer-storage Red Blood Cell Units25.17

Days to First Bowel Movement

Subjects were randomized for RECESS no earlier than one calendar day before the planned date of surgery, and were followed until post-operative Day 28, death, or study withdrawal, whichever occurred first. In some cases the surgery was postponed after randomization had already occurred. If surgery did not occur within 30 days after randomization, the subject ended the study and was not considered evaluable. If surgery did occur within 30 days after randomization, and the subject received at least one RBC transfusion between randomization and 96 hours after the end of surgery, the subject was considered evaluable. Therefore, in a few evaluable subjects, post-operative Day 28 could be nearly two months after the date of randomization. The times in the time-to-event analyses are from randomization to first post-operative bowel movement. (NCT00991341)
Timeframe: Through post-operative day 28, hospital discharge, or death, whichever occurs first

Interventiondays (Mean)
Shorter-storage Red Blood Cell Units5.89
Longer-storage Red Blood Cell Units6.62

Days to First Solid Food

Subjects were randomized for RECESS no earlier than one calendar day before the planned date of surgery, and were followed until post-operative Day 28, death, or study withdrawal, whichever occurred first. In some cases the surgery was postponed after randomization had already occurred. If surgery did not occur within 30 days after randomization, the subject ended the study and was not considered evaluable. If surgery did occur within 30 days after randomization, and the subject received at least one RBC transfusion between randomization and 96 hours after the end of surgery, the subject was considered evaluable. Therefore, in a few evaluable subjects, post-operative Day 28 could be nearly two months after the date of randomization. The times in the time-to-event analyses are from randomization to first post-operative solid food. (NCT00991341)
Timeframe: Through post-operative day 28, hospital discharge, or death, whichever occurs first

Interventiondays (Mean)
Shorter-storage Red Blood Cell Units5.73
Longer-storage Red Blood Cell Units6.18

The Change in the Composite Multiple Organ Dysfunction Score (MODS) From the Pre-operative Baseline. The Worst Post-operative Values of Each Component of MODS Will be Used to Calculate the Change in MODS.

The follow-up MODS used to calculate 7-day ΔMODS from pre-op baseline was based on the worst value of each component of MODS observed through post-op day 7, hospital discharge, or death, whichever occurred first, even if a subject's worst values for different components occurred on different dates. Subjects who died during this time period were assigned the worst possible follow-up MODS score, 24 points, and each component of MODS was set at 4, which is the worst score. If a subject did not die during this time period but had at least one day where the Glasgow Coma Score couldn't be scored [subject sedated; neurologic function not normal by pre-op history (prior stroke, tumor or trauma sequelae, cognitively challenged, behavioral disorder, etc.) or intra-op history, but currently unable to assess because of sedation], then a post-op MODS score was set to missing and a 7-day ΔMODS was not computed. The total MODS score ranges from 0 (best possible) to 24 points (worst possible). (NCT00991341)
Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

InterventionMOD score points (Mean)
Shorter-storage Red Blood Cell Units8.49
Longer-storage Red Blood Cell Units8.66

Ventilation Duration

Because some subjects may experience multiple periods of ventilator use, the total duration that they were on a ventilator was compared between the two groups. (NCT00991341)
Timeframe: Through post-operative day 28, hospital discharge, or death, whichever occurs first

Interventiondays (Mean)
Shorter-storage Red Blood Cell Units2.7
Longer-storage Red Blood Cell Units2.8

48 Hour Sodium Nitrite Infusion Safety as Determined by Number of Participants With No Adverse Events

The primary end points will be to determine if a) a 48-hour sodium nitrite infusion is tolerated without a decrease in mean arterial blood pressure by 15mmHg for greater than 2 hours or development of methemoglobin greater than 5% and b) a 48-hour sodium nitrite infusion is safe as determined by monitoring for adverse events (NCT01033227)
Timeframe: 48 hours from start of infusion

InterventionParticipants (Count of Participants)
No Drug3
Sodium Nitrite Injection, USP2

Change in Hemoglobin Level

Change in plasma hemoglobin (Hb) level after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days

Interventiongm/dL (Mean)
Simvastatin, Dose Level 1-0.2
Simvastatin, Dose Level 20.1
Simvastatin, Dose Level 3-0.4

Change in Plasma Hs-CRP Levels

Change in plasma high sensitivity C-reactive protein levels in subjects treated with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days

Interventionmg/L (Mean)
Simvastatin, Dose Level 1-7.7
Simvastatin, Dose Level 2-3.6

Change in Plasma IL-6 Levels

Change in plasma IL-6 level after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days

Interventionpg/mL (Mean)
Simvastatin, Dose Level 1-0.6
Simvastatin, Dose Level 2-0.3

Change in Plasma NOx Levels

Measurements of the levels of plasma nitric oxide metabolites (NOx), high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), vascular cell adhesion molecule-1 (VCAM-1), tissue factor (TF) and vascular endothelial growth factor (VEGF)were performed before and after simvastatin treatment. Changes in mean plasma biomarker levels were assessed for each dose level; however, dose level 3 results were not analyzed, as only 2 subjects were enrolled in this dose group. (NCT00508027)
Timeframe: Baseline, 21 days

Interventionmicromolar (Mean)
Simvastatin, Dose Level 17
Simvastatin, Dose Level 219.7

Change in Plasma TF Levels

Change in plasma tissue factor (TF) levels after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days

Interventionpg/mL (Mean)
Simvastatin, Dose Level 1-9
Simvastatin, Dose Level 2-36

Change in Plasma VCAM1 Levels

Change in plasma vascular cellular adhesion molecule-1 levels after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days

Interventionng/mL (Mean)
Simvastatin, Dose Level 1-44
Simvastatin, Dose Level 2-86

Change in Plasma VEGF Levels

Change in plasma vascular endothelial adhesion molecule-1 levels after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days

Interventionpg/mL (Mean)
Dose Level 1-164
Dose Level 2-30

Change in Serum Alanine Transaminase (ALT) Levels

Change in serum alanine transaminase (ALT) after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days

InterventionU/L (Mean)
Simvastatin, Dose Level 14
Simvastatin, Dose Level 23
Simvastatin, Dose Level 3-3

Change in Serum Creatine Kinase Levels

Change in serum creatine kinase (CK) levels after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days

InterventionU/L (Mean)
Simvastatin, Dose Level 157
Simvastatin, Dose Level 220
Simvastatin, Dose Level 362

Change in Serum Creatinine Levels

Change in serum creatinine (Cr) levels after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days

Interventionmg/dL (Mean)
Simvastatin, Dose Level 10.03
Simvastatin, Dose Level 20.04
Simvastatin, Dose Level 3-0.1

Change in Total Cholesterol Level

Change in serum total cholesterol level after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days

Interventionmg/dL (Mean)
Simvastatin, Dose Level 1-16
Simvastatin, Dose Level 2-18
Simvastatin, Dose Level 3-18

Reviews

3 reviews available for nitrites and Hemolysis

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation.
    Free radical biology & medicine, 2004, Mar-15, Volume: 36, Issue:6

    Topics: Anemia, Hemolytic; Biological Availability; Blood Circulation; Erythrocyte Membrane; Hemoglobins; He

2004
The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation.
    Free radical biology & medicine, 2004, Mar-15, Volume: 36, Issue:6

    Topics: Anemia, Hemolytic; Biological Availability; Blood Circulation; Erythrocyte Membrane; Hemoglobins; He

2004
The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation.
    Free radical biology & medicine, 2004, Mar-15, Volume: 36, Issue:6

    Topics: Anemia, Hemolytic; Biological Availability; Blood Circulation; Erythrocyte Membrane; Hemoglobins; He

2004
The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation.
    Free radical biology & medicine, 2004, Mar-15, Volume: 36, Issue:6

    Topics: Anemia, Hemolytic; Biological Availability; Blood Circulation; Erythrocyte Membrane; Hemoglobins; He

2004
The red blood cell and vascular function in health and disease.
    Antioxidants & redox signaling, 2004, Volume: 6, Issue:6

    Topics: Adenosine Triphosphate; Animals; Cell Adhesion; Cell-Free System; Endothelium, Vascular; Erythrocyte

2004

Trials

2 trials available for nitrites and Hemolysis

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Transfusion of stored autologous blood does not alter reactive hyperemia index in healthy volunteers.
    Anesthesiology, 2012, Volume: 117, Issue:1

    Topics: Adult; Blood Preservation; Blood Transfusion, Autologous; Cross-Over Studies; Female; Hemolysis; Hum

2012

Other Studies

35 other studies available for nitrites and Hemolysis

ArticleYear
Garcinielliptone FC: Selective anti-amastigote and immunomodulatory effects on macrophages infected by Leishmania amazonensis.
    Toxicology in vitro : an international journal published in association with BIBRA, 2020, Volume: 63

    Topics: Animals; Antiprotozoal Agents; Cell Survival; Cells, Cultured; Erythrocytes; Female; Hemolysis; Immu

2020
Effects of isopentyl ferulate on oxidative stress biomarkers and a possible GABAergic anxiolytic-like trait in Swiss mice.
    Chemico-biological interactions, 2018, Jun-01, Volume: 289

    Topics: Animals; Anti-Anxiety Agents; Antioxidants; Artemia; Ascorbic Acid; Behavior, Animal; Biomarkers; Ca

2018
[Magnetic-laser influence on the system of nitric oxide and contractile activity of smooth muscles of rat aorta under hypertension].
    Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994), 2012, Volume: 58, Issue:6

    Topics: Acetylcholine; Animals; Aorta; Erythrocytes; Hemoglobins; Hemolysis; Hypertension; Lasers; Low-Level

2012
Erythrocyte nitric oxide synthase as a surrogate marker for mercury-induced vascular damage: the modulatory effects of naringin.
    Environmental toxicology, 2014, Volume: 29, Issue:11

    Topics: Antioxidants; Arginine; Biomarkers; Environmental Pollutants; Erythrocytes; Flavanones; Glucosephosp

2014
Increased erythrocytes by-products of arginine catabolism are associated with hyperglycemia and could be involved in the pathogenesis of type 2 diabetes mellitus.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Adult; Aged; Arginine; Blood Glucose; Carbon Isotopes; Case-Control Studies; Citrulline; Diabetes Me

2013
Predicting storage-dependent damage to red blood cells using nitrite oxidation kinetics, peroxiredoxin-2 oxidation, and hemoglobin and free heme measurements.
    Transfusion, 2015, Volume: 55, Issue:12

    Topics: Blood Preservation; Erythrocytes; Heme; Hemoglobins; Hemolysis; Humans; Kinetics; Nitrites; Oxidatio

2015
The Impact of Surgery and Stored Red Blood Cell Transfusions on Nitric Oxide Homeostasis.
    Anesthesia and analgesia, 2016, Volume: 123, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Loss, Surgical; Down-Regulation; Erythrocyte Trans

2016
Bergenin from Peltophorum dubium: Isolation, Characterization, and Antioxidant Activities in Non-Biological Systems and Erythrocytes.
    Medicinal chemistry (Shariqah (United Arab Emirates)), 2017, Volume: 13, Issue:6

    Topics: Animals; Antioxidants; Benzopyrans; Benzothiazoles; Biphenyl Compounds; Electron Transport; Erythroc

2017
Antimicrobial and anti-inflammatory activities of designed antimicrobial peptide P18 analogues.
    Protein and peptide letters, 2008, Volume: 15, Issue:8

    Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antimicrobial Cationic Pept

2008
Plant secondary metabolites.
    Methods in molecular biology (Clifton, N.J.), 2007, Volume: 393

    Topics: Alkaloids; Biological Products; Calibration; Canavanine; Chemistry Techniques, Analytical; Chlorogen

2007
Inhaled nitrite reverses hemolysis-induced pulmonary vasoconstriction in newborn lambs without blood participation.
    Circulation, 2011, Feb-15, Volume: 123, Issue:6

    Topics: Administration, Inhalation; Animals; Animals, Newborn; Hemoglobins; Hemolysis; Hypertension, Pulmona

2011
Protective effect of pravastatin against mercury induced vascular cells damage: erythrocytes as surrogate markers.
    Environmental toxicology and pharmacology, 2012, Volume: 34, Issue:2

    Topics: Adult; Antioxidants; Catalase; Cells, Cultured; Environmental Pollutants; Erythrocytes; Glutathione

2012
Angeli's salt counteracts the vasoactive effects of elevated plasma hemoglobin.
    Free radical biology & medicine, 2012, Dec-15, Volume: 53, Issue:12

    Topics: Animals; Blood Platelets; Blood Pressure; Dogs; Erythrocytes; Heart Rate; Hemolysis; Leukocytes; Met

2012
Premature atherosclerosis in children with β-thalassemia major.
    Journal of pediatric hematology/oncology, 2012, Volume: 34, Issue:8

    Topics: Adolescent; Age of Onset; Atherosclerosis; beta-Thalassemia; Biomarkers; Blood Glucose; Carotid Inti

2012
Oxidative stress-induced posttranslational modifications of human hemoglobin in erythrocytes.
    Archives of biochemistry and biophysics, 2013, Jan-01, Volume: 529, Issue:1

    Topics: Aldehydes; Amino Acid Sequence; Cells, Cultured; Dose-Response Relationship, Radiation; Erythrocyte

2013
Hypochlorous acid-induced oxidative damage of human red blood cells: effects of tert-butyl hydroperoxide and nitrite on the HOCl reaction with erythrocytes.
    Bioelectrochemistry (Amsterdam, Netherlands), 2002, Volume: 58, Issue:2

    Topics: Acetylcholinesterase; Drug Synergism; Erythrocyte Membrane; Erythrocytes; Glutathione; Hemolysis; Hu

2002
Age-related increase in resistance to acute Trypanosoma cruzi infection in rats is associated with an appropriate antibody response.
    Scandinavian journal of immunology, 2003, Volume: 58, Issue:2

    Topics: Age Factors; Animals; Antibodies, Protozoan; Chagas Disease; Hemolysis; Immunity, Innate; Interferon

2003
[The effects of nitrite on adenine compounds in the human blood hemolysates].
    Postepy biochemii, 1962, Volume: 8

    Topics: Adenine; Hemolysis; Humans; Nitrites

1962
Prallethrin induced biochemical changes in erythrocyte membrane and red cell osmotic haemolysis in human volunteers.
    Chemosphere, 2007, Volume: 67, Issue:6

    Topics: Adult; Cholesterol; Erythrocyte Membrane; Hemolysis; Humans; Male; Membrane Lipids; Middle Aged; Nit

2007
Peroxidative hemolysis of red blood cells from patients with abetalipoproteinemia (acanthocytosis).
    The Journal of clinical investigation, 1967, Volume: 46, Issue:3

    Topics: Abetalipoproteinemia; Adult; Animals; Barbiturates; Carbon Monoxide; Chromatography, Gas; Chromatogr

1967
Erythrocyte membrane alterations as the basis of chlorate toxicity.
    Toxicology, 1984, Volume: 30, Issue:2

    Topics: Chlorates; Electrophoresis, Polyacrylamide Gel; Erythrocyte Membrane; Glutathione; Hemolysis; Humans

1984
Prevention by 3-N-ribosyluric acid of the oxidation of bovine hemoglobin by sodium nitrite.
    Archives of biochemistry and biophysics, 1984, Volume: 232, Issue:1

    Topics: Animals; Ascorbic Acid; Cattle; Erythrocytes; Glutathione; Hemolysis; Hydrogen Peroxide; In Vitro Te

1984
Group B streptococcal beta-hemolysin induces nitric oxide production in murine macrophages.
    The Journal of infectious diseases, 2000, Volume: 182, Issue:1

    Topics: Animals; Bacterial Proteins; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Induction; He

2000
Differentiation of Gemella haemolysans (Thjøtta and Bøe 1938) Berger 1960, from Streptococcus morbillorum (Prevot 1933) Holdeman and Moore 1974.
    Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology, 1986, Volume: 261, Issue:3

    Topics: Antigens, Bacterial; Epitopes; Hemolysis; Nitrites; Oxidation-Reduction; Streptococcaceae; Streptoco

1986
Oxidative activity of hydroxylated primaquine analogs. Non-toxicity to glucose-6-phosphate dehydrogenase-deficient human red blood cells in vitro.
    Biochemical pharmacology, 1986, Apr-01, Volume: 35, Issue:7

    Topics: Adenosine Triphosphate; Adult; Aminoquinolines; Erythrocytes; Glucosephosphate Dehydrogenase Deficie

1986
Enumeration of fecal Clostridium perfringens spores in egg yolk-free tryptose-sulfite-cycloserine agar.
    Applied microbiology, 1974, Volume: 27, Issue:3

    Topics: Agar; Anaerobiosis; Bacteriological Techniques; Cell Count; Clostridium; Clostridium perfringens; Cu

1974
Nitroprusside produces cyanide poisoning via reaction with hemoglobin.
    The Journal of pharmacology and experimental therapeutics, 1974, Volume: 191, Issue:3

    Topics: Animals; Cyanides; Erythrocytes; Female; Ferricyanides; Hemoglobins; Hemolysis; Humans; Lethal Dose

1974
Isolation and description of a haemolytic species of Neisseria (N. ovis) from cattle with infectious keratoconjunctivitis.
    Acta pathologica et microbiologica Scandinavica. Section B: Microbiology and immunology, 1972, Volume: 80, Issue:1

    Topics: Animals; Catalase; Cattle; Cattle Diseases; Disaccharides; DNA; Drug Resistance, Microbial; Hemolysi

1972
Effect of methemoglobin on in vivo RBC lipid peroxidation.
    Aerospace medicine, 1973, Volume: 44, Issue:1

    Topics: Animals; Catalase; Erythrocytes; Female; Hemoglobinuria; Hemolysis; Hyperbaric Oxygenation; Lipid Me

1973
Detection and measurement of total bilirubin in serum, with use of surfactants as solubilizing agents.
    Clinical chemistry, 1974, Volume: 20, Issue:4

    Topics: Azo Compounds; Benzoates; Bilirubin; Caffeine; Evaluation Studies as Topic; Hemoglobins; Hemolysis;

1974
Red-cell catalase and the production of methaemoglobin, Heinz bodies and changes in osmotic fragility due to drugs.
    Acta haematologica, 1971, Volume: 45, Issue:5

    Topics: Aniline Compounds; Ascorbic Acid; Azides; Blood Glucose; Catalase; Chlorates; Erythrocytes; Glucosep

1971
Cobalt salts: effects in cyanide and sulfide poisoning and on methemoglobinemia.
    Toxicology and applied pharmacology, 1969, Volume: 15, Issue:3

    Topics: Animals; Chlorides; Cobalt; Cyanides; Erythrocytes; Female; Hemolysis; Methemoglobin; Methemoglobine

1969
[On the reaction between homoglobin and sodium nitrite].
    Acta biologica et medica Germanica, 1967, Volume: 19, Issue:6

    Topics: Animals; Catalase; Fluorides; Hemoglobins; Hemolysis; Humans; Hydrogen Peroxide; Hydrogen-Ion Concen

1967
[Oxidative hemolysis in the newborn. 3. On the sensitivity of hemoglobin to different oxidizing agents].
    Bollettino della Societa italiana di biologia sperimentale, 1968, Dec-31, Volume: 44, Issue:24

    Topics: Hemoglobins; Hemolysis; Humans; Infant, Newborn; Infant, Newborn, Diseases; Methemoglobin; Methylene

1968
Biological properties of alpha-toxin mutants of Staphylococcus aureus.
    Journal of bacteriology, 1966, Volume: 92, Issue:3

    Topics: Antibodies; Coagulase; Dermatitis, Contact; Erythrocytes; Hemolysis; Injections, Intraperitoneal; Mu

1966